Drugs‎ > ‎

Abciximab

Indications
  • prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention
  • short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention
Administration/Absorption
  • IV injection/infusion
Dosage
  • initially by intravenous injection over 1 minute, 250 micrograms/kg, then by intravenous infusion, 125 nanograms/kg/minute (max. 10 micrograms/minute)
Distribution

Mechanism
Excretion
  • plasma half life of about ten minutes, with a second phase half life of about 30 minutes
  • but due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks
Side effects
  • bleeding manifestations; nausea, vomiting, hypotension, bradycardia, chest pain, back pain, headache, fever, puncture site pain, thrombocytopenia
  • rarely cardiac tamponade, adult respiratory distress, hypersensitivity reactions
Interactions

Contraindications

Comments